• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

12 de June de 2015
Ann Oncol. 2015 Sep;26(9):1987-1993. doi: 10.1093/annonc/mdv252.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2015-06-12 10:00:002015-06-12 10:00:00Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

A novel role for an RCAN3-derived peptide as a tumor suppressor in breast cancer

29 de April de 2015
Carcinogenesis. 2015 Jul;36(7):792-9. doi: 10.1093/carcin/bgv056.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2015-04-29 10:00:002015-04-29 10:00:00A novel role for an RCAN3-derived peptide as a tumor suppressor in breast cancer

Multi-target angiokinase inhibitors to fight resistance

9 de December de 2014
Cell Cycle. 2014;13(17):2649-50. doi: 10.4161/15384101.2014.954216.NO…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2014-12-09 11:00:002014-12-09 11:00:00Multi-target angiokinase inhibitors to fight resistance

Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis

2 de October de 2014
Nat Commun. 2014 Oct 1;5:5054. doi: 10.1038/ncomms6054.ABSTRACTMetastasis…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2014-10-02 10:00:002014-10-02 10:00:00Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype

7 de February de 2014
EMBO Mol Med. 2014 Apr;6(4):539-50. doi: 10.1002/emmm.201303214.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2014-02-07 11:00:002014-02-07 11:00:00Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype

Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets

31 de December de 2013
Cancer Metastasis Rev. 2014 Mar;33(1):345-51. doi: 10.1007/s10555-013-9468-y.ABSTRACTNeuroendocrine…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-12-31 11:00:002013-12-31 11:00:00Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets

Antiangiogenic therapies: going beyond their limits

21 de December de 2013
Cancer Discov. 2014 Jan;4(1):31-41. doi: 10.1158/2159-8290.CD-13-0199.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-12-21 11:00:002013-12-21 11:00:00Antiangiogenic therapies: going beyond their limits

The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors

27 de November de 2013
Clin Cancer Res. 2014 Feb 1;20(3):658-67. doi: 10.1158/1078-0432.CCR-13-1131.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-11-27 11:00:002013-11-27 11:00:00The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors

Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis

18 de September de 2013
J Exp Med. 2013 Sep 23;210(10):1937-45. doi: 10.1084/jem.20121571.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-09-18 10:00:002013-09-18 10:00:00Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis

Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors

14 de August de 2013
BMC Cancer. 2013 Aug 10;13:382. doi: 10.1186/1471-2407-13-382.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-08-14 10:00:002013-08-14 10:00:00Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors

Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

8 de May de 2013
Int J Cancer. 2013 Nov 15;133(10):2464-72. doi: 10.1002/ijc.28259.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-05-08 10:00:002013-05-08 10:00:00Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches

6 de March de 2013
Clin Cancer Res. 2013 Jun 1;19(11):2842-9. doi: 10.1158/1078-0432.CCR-12-3458.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-03-06 11:00:002013-03-06 11:00:00Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches
Page 4 of 7«‹23456›»

Filter by categories

  • Alemany’s & Piulats’s lab (131)
  • Antolin's lab (36)
  • Aytes's Lab (24)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sureda's & Farre's Lab (259)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}